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Portal hypertension has traditionally been viewed as a progres-
sive process, involving ultrastructural changes including ﬁbrosis,
nodule formation, and vascular thrombosis, leading to increased
intrahepatic resistance to ﬂow. However, it is increasingly recog-
nized that a signiﬁcant component of this vascular resistance
results from a dynamic process, regulated by complex interac-
tions between the injured hepatocyte, the sinusoidal endothelial
cell, the Kupffer cell and the hepatic stellate cell, which impact on
sinusoidal calibre. Recent ﬁndings suggest these haemodynamic
ﬁndings are most marked in patients with superimposed inﬂam-
mation. The precise mechanisms for vascular dysfunction in cir-
rhosis with superimposed inﬂammation remain to be fully
elucidated but several studies over the past decade have started
to generate the hypothesis that inﬂammation may be a key medi-
ator of the pathogenesis and severity of portal hypertension in
this context. This review provides a comprehensive overview of
the biological mechanisms for inﬂammation playing a key role
in the severity of portal hypertension, and illustrates potential
novel therapies that act by modifying these processes.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V.
Introduction
Portal hypertension is a milestone in the progression of cirrhosis
and heralds the onset of the most fatal complications of liver
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E-mail address: r.jalan@ucl.ac.uk (R. Jalan).disease such as variceal haemorrhage (VH), hepatic encephalopa-
thy, and ascites. The pathobiology of portal hypertension involves
changes in hepatic architecture leading to increased intrahepatic
resistance to ﬂow. Furthermore, insights into the vascular biology
of cirrhosis have demonstrated that a signiﬁcant proportion of
intrahepatic resistance is modiﬁable, as a consequence of sinusoi-
dal endothelial dysfunction and the effect of contractile myoﬁ-
broblasts and pericytes [1,2].
The development of robust techniques for the measurement
of sinusoidal pressure, through the hepatic venous pressure gra-
dient (HVPG), led to landmark observations into the natural his-
tory of portal hypertension, and clear associations were found
between the degree of portal hypertension, and complications
of cirrhosis and mortality [3,4]. However, the contextual basis
of these longitudinal studies was in ‘early’ cirrhosis, prior to the
development of complications of advanced cirrhosis such as bac-
terial infection and renal failure. Recent insights into the natural
history of cirrhosis have led to a re-appraisal of the pathophysio-
logical basis of portal hypertension in advanced cirrhosis. Indeed,
it is increasingly recognized that the description of cirrhosis rep-
resents a diverse group of patients, with varying degrees of hepa-
tic ﬁbrosis and systemic manifestations [5].
These observations are complimented by the recent descrip-
tion of the syndrome of acute-on-chronic liver failure (ACLF),
where hepatic and systemic inﬂammation lead to an acute dete-
rioration of liver function, regardless of underlying stage of cir-
rhosis, either secondary to superimposed liver injury or due to
precipitating factors such as infection [6]. The large, prospective
CANONIC study deﬁned ACLF as an acute decompensation of cir-
rhosis, associated with (i) single- or multi-organ failure, and (ii)
high 28-day mortality (>15%) [7]. Organ failure was deﬁned based
on a modiﬁed SOFA score adapted for patients with cirrhosis
(CLIF-SOFA score). Thus, ACLF is distinguished from acute
decompensation of cirrhosis (AD) by the presence of organ
failure, associated with a marked systemic inﬂammatory
response, leading to a high short-term mortality. Conceptually,
the development of ACLF marks a departure from the traditional14 vol. 61 j 155–163
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stepwise view of progression of cirrhosis and portal hyperten-
sion. In the CANONIC study, patients with previously well-com-
pensated cirrhosis had a signiﬁcantly higher mortality following
the development of ACLF than those with decompensated cirrho-
sis, marking a sharp contrast to the dogma of progressive liver
disease. Moreover, patients with ACLF have been shown to have
the highest portal pressures [8,9], although the CANONIC data
also demonstrated that GI bleeding is not a major feature of ACLF,
suggesting that the pathophysiological relevance of portal hyper-
tension and intrahepatic resistance in ACLF may relate to
decreased liver perfusion and consequently liver failure.
This aim of this review is to describe recent developments in
the pathobiology of portal hypertension, in the context of these
recent insights into ACLF. This article is timely, since it builds
on this work deﬁning ACLF and describing the key role of innate
immunity and inﬂammation in the evolution of this syndrome. As
such, this review seeks to delineate the role of innate inﬂamma-
tion on portal hypertension, and describes novel strategies and
potential targets for therapy.
Key Points
• Portal hypertension is associated with bacterial 
translocation (BT) and innate immune activation in 
cirrhosis
• Inflammation is thought to play a causal role in portal 
hypertension since bacterial infection increases portal 
pressure, and antibiotics and anti TNF-α therapy 
decrease portal pressure
• Mechanisms include BT leading to TLR4-mediated 
Kupffer cell activation and oxidative stress, with 
downstream effects on eNOS function and stellate cell 
contractility
• Novel therapies for portal hypertension acting on these 
processes include rifaximin, FXR agonists, statins and 
TLR4 antagonists
Bacterial translocation, portal hypertension, and variceal
haemorrhage
It is increasingly recognised that the unique anatomical location
and vascular supply of the liver lends itself to frequent exposure
to intestinal bacteria and bacterial products, particularly in the
context of advanced cirrhosis and portal hypertension [10]. A
broader role for gut microbiota in the development of complica-
tions of cirrhosis, such as hepatic encephalopathy and spontane-
ous bacterial peritonitis (SBP), has been recognised for some
years. However, the immunobiology of gut bacterial translocation
(BT) has only recently become a target of scrutiny, with down-
stream innate inﬂammatory responses being shown to play a role
in processes such as hepatic ﬁbrogenesis and carcinogenesis in
animal models.
Bacterial translocation (BT) is deﬁned as the passage of both
viable and non-viable microbes and microbial products, such as
endotoxin, from the intestinal lumen through the mucosa into
mesenteric lymph nodes (MLNs) and other organs. As such, it is
increasingly evident that BT is common in cirrhosis, and may156 Journal of Hepatology 201be a pathogenic event in several complications of cirrhosis. It
has been shown that BT occurs in approximately 30–40% of
patients with advanced cirrhosis. Indeed, positive bacterial cul-
tures of mesenteric lymph nodes were found in 30.8% of patients
with Child-Pugh C cirrhosis, compared to 8.6% of non-cirrhotics
[11]. Similarly the surrogate marker of BT, lipopolysaccharide
(LPS)-binding protein (LBP), was observed to be increased in
42% of cirrhotic patients [12]. In rodents, acute portal hyperten-
sion due to portal vein ligation precipitates BT [13], and in
humans the degree of portal hypertension predicts the occur-
rence of SBP [14], suggesting that portal hypertension plays a
key role in the development of BT. It has also been recognized
for some years that bacterial infections are associated with a
poorer prognosis from variceal haemorrhage (VH) [15]. More-
over, BT is associated with other portal hypertension-related
complications, such as hepatic encephalopathy and spontaneous
bacterial peritonitis (SBP) [10].
Downstream signals following BT are numerous and complex,
but the immediate and dominant pathways are highly conserved
innate immune signals stimulated by exposure to microbial prod-
ucts, or pathogen-associated molecular patterns (PAMPs) leading
to activation of Toll-like receptors (TLRs) on parenchymal and
non-parenchymal cells (Fig. 1). These receptors are widely
expressed in the liver, but Kupffer cells (KCs) are the primary cells
that respond to PAMP exposure, and adopt a pro-inﬂammatory
phenotype through TLR-mediated signalling, producing cytokines
such as TNF-a, IL-1, IL-6, and IL-12 [16]. This dysregulated pro-
inﬂammatory cytokine response to BT is associated with severe
portal hypertension in cirrhosis. Serum bacterial DNA levels, as
a surrogate marker of BT, are correlated with severity of inﬂam-
mation and portal hypertension in cirrhosis [17]. Moreover, in
patients with SBP, elevated levels of catecholamines and TNF-a
are associated with higher HVPG [18].
A causal relationship between BT-mediated inﬂammation and
portal hypertension is further suggested in rodent models, where
the administration of bacterial LPS leads to exacerbation of portal
hypertension [19], whereas the use of both norﬂoxacin and rifax-
imin decrease complications of cirrhosis [20,21]. In humans, two
studies demonstrate a beneﬁcial effect of antibiotics on portal
pressure, although neither is placebo-controlled [22,23]. The con-
trolled studies of antibiotics in portal hypertension failed to show
any beneﬁt, although both showed a trend towards HVPG reduc-
tion, suggesting they were inadequately powered to demonstrate
an effect [12,24]. Direct inhibition of TNF-a in patients with ACLF
due to alcoholic hepatitis (AH), although not adopted due to
increased overall rates of infection, has also been shown to lead
to a sustained reduction in portal pressure [25].
Therefore, BT-mediated inﬂammation is suggested to be an
important mediator of portal hypertension in advanced cirrhosis.
Several markers of systemic inﬂammation are elevated in
advanced cirrhosis, and correlate with portal hypertension and
mortality, including serum CRP and IL-6 levels [26,27]. The mech-
anisms whereby an enhanced pro-inﬂammatory cytokine
response to BT in cirrhosis may potentiate vascular dysfunction
and intrahepatic resistance in cirrhosis are discussed below.Mechanisms of intrahepatic resistance in hepatic
inﬂammation
The hallmark of cirrhosis is nodular ﬁbrosis and scarring, leading
to architectural distortion of sinusoidal blood ﬂow, however the4 vol. 61 j 155–163
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Fig. 1. The role of bacterial translocation (BT) in the pathobiology of portal hypertension. Gut-derived bacterial products (PAMPs) stimulate the hepatic innate immune
system through toll-like receptor (TLR) 4 signaling, predominantly on hepatic stellate cells (HSCs) and Kupffer cells (KCs). TLR-4 mediated stimulation of HSCs leads to HSC
activation and a ﬁbrogenic, contractile phenotype, as well as KC activation through paracrine chemokine secretion (CCL2-CCL5). In turn, KCs produce TGF-b, stimulating
ﬁbrogenesis, and the pro-inﬂammatory cytokines TNF-a and IL-6, propagating hepatic inﬂammation. KCs also produce reactive oxygen species (ROS), leading to the
generation of other reactive nitrogen species and local tissue damage. HSCs also interact with sinusoidal endothelial cells (SECs) in the sinusoidal niche. The SEC tonically
produces nitric oxide (NO), which maintains the HSC in a quiescent phenotype. A reduction in SEC-derived NO production contributes to HSC activation and consequent
ﬁbrosis/HSC contractility. The activated HSC produces local mediators (VEGF, angiopoietin-1), which stimulate angiogenesis in the SEC and other local cells, which in turn
propagates portal hypertension.
JOURNAL OF HEPATOLOGYkey role of intrahepatic vascular tone in regulating sinusoidal
pressure is well established. Molecular mechanisms of this
increase in vascular tone include an imbalance of vasodilator
and vasoconstrictor compounds, dysfunction of sinusoidal endo-
thelium, and activation of contractile elements in vascular
smooth muscle, portal myoﬁbroblasts, and hepatic stellate cells
(HSCs). Nitric oxide (NO) has been demonstrated to be a key reg-
ulator of intrahepatic vascular tone, and NO production from
endothelial nitric oxide synthase (eNOS) in the sinusoidal endo-
thelial cell (SEC) is decreased in cirrhosis [28,29]. However, eNOS
protein levels remain unchanged, suggesting that NO production
is reduced due to either post-translational modiﬁcation of eNOS
enzyme, such as decreased eNOS phosphorylation, or altered lev-
els of endogenous eNOS cofactors/inhibitors. Several of these
have been described in cirrhosis, including elevated levels of
eNOS inhibitors asymmetric dimethylarginine (ADMA) and cave-
olin-1, and decreased levels of the eNOS co-factor tetrahydrobi-
opterin [30–32] (Fig. 2).
Following its generation in SECs, NO modulates vascular tone
through a vasodilator effect on adjacent vascular smooth muscle.
However, intrahepatic vascular tone is also regulated by HSCs,
which adopt a myoﬁbroblastic phenotype upon activation [2].
These activated HSCs have extensive coverage of the sinusoidal
network through cellular extensions and can modulate intrahe-
patic resistance through contractility. Activated HSCs areJournal of Hepatology 201responsive to endogenous vasoconstrictors (e.g., endothelins,
norepinephrine, angiotensin II, leukotrienes, thromboxane A2)
leading to increased contractility and intrahepatic resistance
[33–36]. The intrahepatic vasculature displays increased
sensitivity to these vasoconstrictors in cirrhosis. Additionally,
the activated HSCs play a key role in angiogenesis, leading to
intrahepatic shunting and vascular collateral formation [37,38].
Hepatic innate immune signaling has been suggested to con-
tribute to portal hypertension through effects on ﬁbrosis, and on
intrahepatic vascular tone. The role of PAMPs in the progression
of ﬁbrosis, in particular through TLR4 signaling, has been exten-
sively studied. TLR4 is expressed on both parenchymal and
non-parenchymal cell types in the liver, and its signaling is
involved in liver injury induced by viral hepatitis, alcoholic and
non-alcoholic steatohepatitis, and cholestatic and drug-induced
liver diseases [16]. Several animal studies support the importance
of TLR4 in liver ﬁbrosis. Knockout mice that are deﬁcient in TLR4,
or in other signaling molecules of the TLR4 pathway such as
CD14, LBP, MyD88, and TRIF, have less liver ﬁbrosis induced by
bile duct ligation (BDL) or carbon tetrachloride (CCl4) than wild
type [21,39,40]. Selective decontamination of gut ﬂora also sup-
presses the increase in plasma LPS and attenuates liver ﬁbrosis
in these rodent models [39].
Although the TLR4 signaling pathway is involved in ﬁbrosis,
the elegant experiments by Seki et al. demonstrate that this is a4 vol. 61 j 155–163 157
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Fig. 2. Nitric oxide (NO) regulates intrahepatic vascular tone, through maintaining hepatic stellate cells (HSCs) in a quiescent phenotype and promoting
vasodilatation through cGMP signaling. Asymmetric dimethylarginine (ADMA) is a paracrine, competitive inhibitor of NO synthesis by endothelial nitric oxide synthase
(eNOS), and is metabolized in the hepatocyte by dimethylarginine dimethylaminohydrolase-1 (DDAH-1). Inﬂammation leads to ROS generation by KCs, which inhibits
DDAH-1 activity thereby leading to eNOS inhibition by ADMA and decreased local NO production. Other molecules such as Caveolin and Akt also contribute to inhibition of
eNOS activity. ROS also interact with free NO generating further reactive nitrogen species (RNS) contributing to local tissue damage and propagating innate immune
signaling through DAMPs. The activated SEC also produces further vasoactive mediators such as endothelin-1 and thromboxanes/leukotrienes, which increase HSC
contractility thereby increasing intrahepatic resistance. Stimulation of Kupffer cells and stellate cells by pathogen associated and damage associated molecular patterns
(PAMPs and DAMPs) further accentuates inﬂammation and generation of ROS, which acts in a feed-forward cycle exacerbating HSC activation and severity of portal
hypertension.
ReviewKC-independent process [39]. By contrast, in more advanced cir-
rhosis, KCs play a more prominent role in the development of
hepatic inﬂammation and oxidative stress, leading to increased
intrahepatic resistance. In alcoholic liver disease (ALD), TLR sig-
naling on KCs leads to the production of pro-inﬂammatory cyto-
kines such as TNF-a, IL-6, and IL-8, initiating both hepatic and
systemic inﬂammation [41]. A further downstream effect of TLR
activation on KCs is the production of reactive oxygen species
(ROS) [42]. KCs also produce vasoactive mediators, predomi-
nantly from the cyclooxygenase-thromboxane A2 pathway, in
response to PAMPs. LPS administration to cirrhotic rats leads to
production of thromboxane A2 and cysteinyl leukotrienes, and
augmented portal hypertension. Moreover, both KC depletion
and treatment with the leukotriene antagonist montelukast abro-
gate portal hypertension in this model [19,43]. There is also evi-
dence of KC activation in humans – in cirrhotic patients a serum158 Journal of Hepatology 201marker of KC activation, sCD163, has been shown to closely cor-
relate with HVPG, severity of liver disease and risk of VH [44].
A further downstream effect of innate immune signaling and
local oxidative stress is on SEC function. As noted above, local
intrahepatic NO production is decreased in cirrhosis, although
expression of the enzyme eNOS in SECs remains normal or
increased. ROS generation in cirrhosis is due to both increased
production from KCs, as well as decreased activity of elimination
systems such as superoxide dismutase [45]. Indeed, gene transfer
of superoxide dismutase has been shown to lower portal pressure
in rodent models of cirrhosis [46]. Oxidative stress leads to
decreased NO bioavailability through a number of mechanisms
– ROS directly interacts with NO leading to the formation of per-
oxynitrite and other reactive nitrogen species [47]. Additionally
ROS leads directly to eNOS dysfunction through eNOS ‘uncou-
pling’ and decreased eNOS phosphorylation, as well as increasing4 vol. 61 j 155–163
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the formation of eNOS inhibitors [47]. Plasma levels of the NOS
inhibitor ADMA are elevated in cirrhosis, and are elevated further
in ACLF due to AH [30]. Moreover, hepatic levels of ADMA corre-
late with HVPG in patients with ACLF, associated with decreased
hepatic expression of dimethylarginine dimethylaminohydro-
lase-1 (DDAH-1) the metabolizing enzyme for ADMA. The
enzyme DDAH-1 is sensitive to oxidative stress [48], hence ROS
production by activated KCs will lead to decreased DDAH-1
expression and activity, and thereby increased levels of the eNOS
inhibitor ADMA, thus decreasing local NO generation. Addition-
ally, hepatic expression of the eNOS inhibitor caveolin-1, and
the eNOS trafﬁcking protein NOSTRIN, are increased in ACLF
and AH compared to patients with decompensated cirrhosis
alone [31,49]. These proteins also decrease eNOS activity and
NO production from SECs. Conversely, pre-treatment of cirrhotic
rats with recombinant HDL, which neutralizes circulating LPS,
leads to a reduction in LPS-induced systemic inﬂammation,
improvement in eNOS-mediated NO generation, and abrogation
of portal hypertension [50].
Hepatocyte cell death through oxidative injury is also likely
to propagate local innate immune signaling through the produc-
tion of damage associated molecular patterns (DAMPs) [51].
These intracellular molecules are responsible for the induction
of ‘sterile’ inﬂammation following tissue injury, and act through
similar downstream pathways to PAMPs, through TLR4 signaling.
There is also direct cross-talk between PAMP and DAMP path-
ways, since bacterial LPS also directly stimulates the release of
DAMPs such as HMGB1 [52]. Therefore, the induction of local
liver injury through BT and innate immunopathology sets into
a motion a feed-forward cycle of PAMP and DAMP mediated
inﬂammation leading to further oxidative stress and vascular
dysfunction.
Thus paracrine communication and matrix-cell interactions in
the sinusoidal niche are key regulators of cellular phenotype and
functional status. The SEC-HSC ‘cross-talk’ has been proposed as a
means of regulating both SEC and HSC activation, since these cells
each maintains the other’s differentiated phenotype. Local NO
production by differentiated SECs promotes HSC quiescence,
and activation of the VEGF-NO pathway in hepatocytes and HSCs
maintains SECs in a quiescent differentiated state [53,54]. Disrup-
tion of paracrine communication in this sinusoidal niche propa-
gates ﬁbrosis and endothelial dysfunction in the cirrhotic liver,
hence strategies to deliver or increase intrahepatic NO are unli-
kely to be sophisticated enough to halt this process without fur-
ther understanding of the signalling pathways involved in these
cellular processes.Systemic circulatory dysfunction and splanchnic
vasodilatation
Portal hypertension is further augmented by vasodilatation of the
splanchnic vascular bed and increased portal venous inﬂow to
the liver. Pre-clinical models suggest that the primary
pathophysiological event is the development of intrahepatic
resistance, which signals to the splanchnic and systemic
vasculature leading to increased expression of VEGF and eNOS
in the mesenteric circulation [55]. Thus, unlike the intrahepatic
circulation, there is an excess of local NO production, and
decreased responsiveness of the mesenteric circulation to
vasoconstrictors.Journal of Hepatology 201The relative contribution of different NOS isoforms to the
enhanced systemic and splanchnic NO production in cirrhosis
remains controversial. Data from rodent studies seem to vary
depending on whether a pre-sinusoidal model of portal hyperten-
sion has been used, such as partial portal vein ligation (PPVL), or a
model of cirrhosis. In the PPVL model, it is clear from studies
using knockout mice that eNOS is responsible for the major part
of the vasodilatation of cirrhosis, rather than inducible NOS
(iNOS) [56,57]. However, these animals may be less representa-
tive of the pathophysiology of advanced cirrhosis, with less sys-
temic inﬂammation and immune dysfunction. In rodents with
biliary cirrhosis and portal hypertension, aortic iNOS expression
is induced by the administration of bacterial LPS [58]. Moreover,
the role of iNOS expression in perivascular cells has recently been
investigated – the adventitial layer of mesenteric vessels in cir-
rhotic rats has been shown to contain increased number of acti-
vated macrophages expressing iNOS [59]. Thus paracrine effects
of iNOS activation in inﬂammatory cells may increase mesenteric
ﬂow in advanced cirrhosis, and thereby augment portal hyper-
tension. This is in direct contrast to the intrahepatic circulation,
where despite upregulation of hepatic iNOS expression following
LPS administration, speciﬁc iNOS antagonists have little effect on
liver blood ﬂow and typically ameliorate liver injury, suggesting
that iNOS does not play a role in maintaining liver perfusion fol-
lowing injury [60,61].
There is indirect evidence in humans for gut-derived bacteria
exacerbating systemic circulatory dysfunction in cirrhosis.
Patients with advanced cirrhosis demonstrate increased systemic
NO production and endotoxinemia following TIPS insertion [62].
Plasma from these patients, when incubated with HUVEC cells,
leads to decreased eNOS activity but increased iNOS activity, sug-
gesting that portal venous bacterial products cause increased sys-
temic NO production and circulatory dysfunction. There is further
indirect evidence from improvement in vascular dysfunction in
cirrhosis with antibiotics. Norﬂoxacin use in cirrhosis has been
shown to signiﬁcantly decrease endotoxin levels, increase mean
arterial blood pressure and systemic vascular resistance, and
decrease NO-mediated forearm vasodilatation [12,22]. In cir-
rhotic rats, aortic eNOS phosphorylation by Akt is decreased by
norﬂoxacin treatment, associated with downregulation of TNF-
a and IL-6 [63].
Systemic and splanchnic vasodilatation may also augment
portal hypertension through systemic vasoactive systems, such
as endocannabinoid (EC) and renin-angiotensin signaling. The
EC system has been shown to contribute to vasodilatation in cir-
rhosis – anandamide has been shown to mediate splanchnic and
systemic vasodilatation in cirrhotic rats through endothelial CB1
receptors [64,65]. Furthermore, in the intrahepatic circulation,
anandamide causes a CB1-mediated, dose-dependent increase
in vasoconstrictor eicosanoids and intrahepatic resistance [66].
Since LPS is a stimulus for EC generation from platelets and mac-
rophages [67], the EC system may be a major contributor to
splanchnic vasodilatation through gut-derived LPS – this hypoth-
esis requires further consideration. A further consequence of sys-
temic circulatory dysfunction is activation of the renin-
angiotensin system, which potentiates intrahepatic resistance
through angiotensin-mediated increases in hepatic ROS forma-
tion and HSC contractility [35,68].
Aside from excess NO generation in the splanchnic circulation,
data from eNOS and iNOS knockout mice suggests that factors
other than NO are also involved in the pathogenesis of arterial4 vol. 61 j 155–163 159
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vasodilatation in cirrhosis [57]. Microparticles (MPs), membrane
vesicles that can affect vascular and inﬂammatory signaling path-
ways, have recently been shown to be increased in the plasma of
cirrhotic patients, and correlate with severity of liver disease and
inﬂammation [69]. Moreover, these MPs impaired the response of
cultured rat aortic rings to vasoconstrictors. Thus, MP signaling
represents a further tier of complexity in the regulation of inﬂam-
mation and vascular function.Novel therapeutic approaches for portal hypertension – a
glimpse of the future
Accordingly, our perspective of portal hypertension and vascular
dysfunction in cirrhosis is evolving from a linear process associ-
ated with progressive ﬁbrosis and the development of complica-
tions, to a dynamic interplay between innate inﬂammatory
responses and the sinusoidal niche, exacerbated by systemic
inﬂammation and endothelial dysfunction. This shift in perspec-
tive, along with the parallel development of advances in immu-
nological and genomic technologies, has opened avenues for
the identiﬁcation of novel therapeutic targets. Shakespeare’s
Hamlet spoke of the future as the ‘‘undiscover’d country’’, and
this allegory applies to opportunities to improve current thera-
pies for the patient with advanced cirrhosis.
The clinical use of antibiotics in cirrhosis represents one such
paradigm shift. Rifaximin, a non-absorbable antibiotic, has been
demonstrated to have a clinically signiﬁcant beneﬁcial effect
when used in combination with lactulose for preventing recur-
rent HE [70]. As described above, BT in cirrhosis leads to stimula-
tion of TLR4-mediated signaling in HSCs, KCs, and SECs.
Interactions between these cells in the sinusoidal niche lead to
activation of HSCs, pro-inﬂammatory cytokine production by
KCs, and angiogenesis by activated SECs. As such, inhibitors of
these signaling pathways, either through selective gut decontam-
ination or TLR-4 antagonism, are attractive targets for portal
hypertension in the context of inﬂammation and ACLF. Rifaximin
decreases ﬁbrosis, angiogenesis, and portal pressure following
BDL injury in mice [21]. Similarly, TLR-4 knockout mice are pro-
tected from ﬁbrosis and portal hypertension following BDL [39].
With regard to systemic TLR-4 antagonists, a randomized con-
trolled trial of the TLR-4 antagonist eritoran in severe sepsis did
not reduce mortality compared with placebo [71]. A greater
understanding of downstream signaling from TLR-4 in the sinu-
soidal niche may facilitate other targets in this pathway. For
example, ﬁbronectin has been found to be a paracrine mediator
from the activated HSC to the SEC, leading to a pro-angiogenic
phenotype [21].
The nuclear bile-acid receptor FXR pathway has also been the
subject of considerable attention over recent years. Bile acid (BA)
signaling, through the FXR pathway in the liver and intestine,
maintains homeostasis of the bile acid pool and prevents chole-
static liver injury [72]. However, BAs also have important effects
on lipid and glucose metabolism, inﬂammation, and vascular
function. There is an FXR-responsive element in the DDAH-1
gene, and FXR agonists have been shown to dose-dependently
increase DDAH-1 expression in hepatocytes [73]. Indeed, the
selective FXR agonist obeticholic acid has been shown to increase
hepatic DDAH-1 expression in cirrhotic rats, leading to improve-
ments in systemic and hepatic vascular dynamics [74]. Early
results from an ongoing multi-centre phase 2a trial of obeticholic160 Journal of Hepatology 201acid in portal hypertension show a trend towards a reduction in
portal pressure [75].
Statins also have beneﬁcial effects on vascular function in cir-
rhosis. Simvastatin has been studied in rodents and humans, and
has been shown to have a portal pressure lowering effect through
a direct effect on eNOS phosphorylation, thereby increasing NO
bioavailability from SECs [76]. Simvastatin also has indirect
effects on hepatic vascular function by increasing expression of
the transcription factor Klf2, which has beneﬁcial downstream
effects such as augmenting eNOS expression and decreasing
expression of pro-inﬂammatory vascular adhesion molecules
such as VCAM1 [77]. Additionally, statins are generally consid-
ered safe in liver disease, and may have other beneﬁcial effects
in chronic liver disease, such as decreasing dyslipidaemic liver
injury, and slowing the progression of hepatocellular cancer
[78]. However, further work is still required before statins can
be widely recommended in liver disease. The degree of reduction
in portal pressure, either with or without propranolol, remains
modest (6–10%), and the clinical signiﬁcance of this magnitude
of portal pressure reduction remains to be established.
Tyrosine kinase inhibitors such as sorafenib, used for the
treatment of hepatocellular carcinoma, have additional effects
on angiogenesis and ﬁbrosis through non-epithelial cells such
as HSCs and SECs. Angiogenesis, as a response to tissue injury
and wound healing, occurs extensively in cirrhosis and is respon-
sible for the formation of varices and other porto-systemic collat-
erals. The processes of ﬁbrosis and angiogenesis are considered
complementary, since activated HSCs secrete pro-angiogenic
mediators such as VEGF and angiopoietin-1 to nearby SECs, facil-
itating new vessel formation [37]. Activated HSCs are also closely
associated with sinusoidal vessels and new vessels, with expan-
sion of contractile HSC ﬁlipodia coverage, thus further exacerbat-
ing sinusoidal resistance and propagating angiogenesis. Early
studies with the multi-kinase inhibitor Sunitinib demonstrated
decreased angiogenesis and ﬁbrosis in rodent models of cirrhosis
[79]. Similar ﬁndings were found with imatinib, another multi-
kinase inhibitor, which decreased HSC activation and portal pres-
sure in BDL cirrhotic rats. Sorafenib, which inhibits multiple
pathways including Raf, PDGF, and VEGF, also led to decreased
liver stiffness and decreased angiogenesis in BDL cirrhotic rats
[80]. Human HSC and SEC co-cultures have shown that sorafenib
impairs HSC-SEC interaction by blocking PGDF mediated angio-
poeitin-1 and ﬁbronectin signaling, leading to decreased ﬁbrosis
and angiogenesis, and further demonstrating the importance of
paracrine signaling in the sinusoidal niche. The only studies in
humans have been uncontrolled observations in patients with
HCC, where decreases in HVPG and portal blood ﬂow have been
noted [81]. In view of the variable tolerability of sorafenib in
patients with cirrhosis and HCC, dose-reduction or novel agents
will be required for usage in advanced cirrhosis.
Finally, the role of transcriptional regulation, and small non-
coding RNAs in particular, in ﬁne-tuning cellular responses to
inﬂammation is also beginning to be appreciated. For example,
regulation of TNF-a production from KCs in ALD involves several
microRNAs (miRs) including miR-155 [82]. Similarly, other key
genes involved in endothelial function, such as DDAH-1, are reg-
ulated by miRs in the context of inﬂammation and oxidative
stress [83]. Targeting of small non-coding RNAs in the liver
through antisense oligonucleotides is a signiﬁcant advance in
small molecule drug discovery and delivery. For example, modi-
ﬁed locked nucleic acid oligonucleotides targeting miR-122 have4 vol. 61 j 155–163
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shown safety and efﬁcacy in humans for decreasing replication of
hepatitis C virus [84]. These technical advances, along with the
knowledge gained from large genomic and transcriptomic
sequencing projects such as ENCODE, have enhanced our knowl-
edge of mechanistic RNA targets and expanded the ‘druggable’
genome [85]. Novel therapies for inﬂammation and portal hyper-
tension may build on the pathways outline above, but may target
transcriptional switches such as small RNAs, since the ‘ﬁne-
tuning’ effect may be more desirable with less toxicity.Conclusion
Thus, systemic inﬂammation and portal hypertension are linked
by endothelial dysfunction and innate immune interactions
within the sinusoidal niche of the injured liver. Our rapidly pro-
gressing knowledge of the mechanisms of liver injury, and host
responses to injury and inﬂammation, are leading to advances
in the management of portal hypertension in advanced cirrhosis.
If we can successfully journey through this ‘undiscover’d coun-
try’, then opportunities beckon for translational research and
novel therapeutics in portal hypertension.Conﬂict of interest
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